Related Experiment Videos
Activation of the secretory pathway leads to a decrease in the intracellular amyloidogenic fragments generated from
D Fukushima1, M Konishi, K Maruyama
1Minase Research Institute, Ono Pharmaceutical Co. Ltd., Osaka, Japan.
Biochemical and Biophysical Research Communications
|July 15, 1993
Summary
Phorbol 12-myristate 13-acetate (PMA) treatment shifts amyloid precursor protein (APP) processing in glioblastoma cells. This metabolic switch reduces intracellular beta-amyloidogenic fragments by favoring secretion over lysosomal pathways.
Area of Science:
- Neuroscience
- Cell Biology
- Biochemistry
Background:
- Amyloid precursor protein (APP) processing is crucial in neurodegenerative diseases.
- Glioblastoma cells exhibit altered APP metabolism.
- The endosomal/lysosomal pathway is a key route for APP degradation.
Purpose of the Study:
- To investigate the effect of phorbol 12-myristate 13-acetate (PMA) on APP processing in human glioblastoma cells.
- To determine if PMA influences the intracellular levels of beta-amyloidogenic fragments.
- To elucidate the pathway shift in APP metabolism induced by PMA.
Main Methods:
- Treatment of human glioblastoma A-172 cells with PMA.
- Analysis of intracellular beta-amyloidogenic fragments derived from APP.
- Assessment of APP trafficking between endosomal/lysosomal and secretory pathways.
Main Results:
- PMA treatment significantly decreased intracellular beta-amyloidogenic fragments in A-172 cells.
- APP processing shifted from the endosomal/lysosomal pathway towards the secretory pathway.
- This suggests a metabolic switch in APP handling following PMA stimulation.
Conclusions:
- PMA activates the secretory pathway for APP, reducing harmful intracellular fragments.
- The findings highlight a potential therapeutic strategy targeting APP metabolism in glioblastoma.
- Glioblastoma A-172 cells demonstrate a modifiable APP processing pathway.